                                                                                                                                   II




                                  113TH CONGRESS
                                     1ST SESSION                            S. 408
                                        To amend title XVIII of the Social Security Act to deliver a meaningful
                                        benefit and lower prescription drug prices under the Medicare program.




                                              IN THE SENATE OF THE UNITED STATES
                                                                 FEBRUARY 28, 2013
                                    Mr. DURBIN (for himself, Mr. REED, and Mr. WHITEHOUSE) introduced the
                                   following bill; which was read twice and referred to the Committee on Finance




                                                                            A BILL
                                  To amend title XVIII of the Social Security Act to deliver
                                     a meaningful benefit and lower prescription drug prices
                                     under the Medicare program.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Medicare Prescription
                                    5 Drug Savings and Choice Act of 2013’’.
                                    6     SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRE-
                                    7                             SCRIPTION DRUG PLAN OPTION.
                                    8              (a) IN GENERAL.—Subpart 2 of part D of title XVIII




                                    9 of the Social Security Act is amended by inserting after
                                                                                             2
                                    1 section 1860D–11 (42 U.S.C. 1395w–111) the following
                                    2 new section:
                                    3            ‘‘MEDICARE             OPERATED PRESCRIPTION DRUG PLAN
                                    4                                                   OPTION
                                    5              ‘‘SEC. 1860D–11A. (a) IN GENERAL.—Notwith-
                                    6 standing any other provision of this part, for each year
                                    7 (beginning with 2014), in addition to any plans offered
                                    8 under section 1860D–11, the Secretary shall offer one or
                                    9 more Medicare operated prescription drug plans (as de-
                                  10 fined in subsection (c)) with a service area that consists
                                  11 of the entire United States and shall enter into negotia-
                                  12 tions in accordance with subsection (b) with pharma-
                                  13 ceutical manufacturers to reduce the purchase cost of cov-
                                  14 ered part D drugs for eligible part D individuals who en-
                                  15 roll in such a plan.
                                  16               ‘‘(b)          NEGOTIATIONS.—Notwithstanding                                    section
                                  17 1860D–11(i), for purposes of offering a Medicare operated
                                  18 prescription drug plan under this section, the Secretary
                                  19 shall negotiate with pharmaceutical manufacturers with
                                  20 respect to the purchase price of covered part D drugs in
                                  21 a Medicare operated prescription drug plan and shall en-
                                  22 courage the use of more affordable therapeutic equivalents
                                  23 to the extent such practices do not override medical neces-
                                  24 sity as determined by the prescribing physician. To the




                                  25 extent practicable and consistent with the previous sen-
                                  26 tence, the Secretary shall implement strategies similar to
                                              •S 408 IS

                                                                                             3
                                    1 those used by other Federal purchasers of prescription
                                    2 drugs, and other strategies, including the use of a for-
                                    3 mulary and formulary incentives in subsection (e), to re-
                                    4 duce the purchase cost of covered part D drugs.
                                    5              ‘‘(c) MEDICARE OPERATED PRESCRIPTION DRUG
                                    6 PLAN DEFINED.—For purposes of this part, the term
                                    7 ‘Medicare operated prescription drug plan’ means a pre-
                                    8 scription drug plan that offers qualified prescription drug
                                    9 coverage and access to negotiated prices described in sec-
                                  10 tion 1860D–2(a)(1)(A). Such a plan may offer supple-
                                  11 mental prescription drug coverage in the same manner as
                                  12 other qualified prescription drug coverage offered by other
                                  13 prescription drug plans.
                                  14               ‘‘(d) MONTHLY BENEFICIARY PREMIUM.—
                                  15                         ‘‘(1) QUALIFIED                     PRESCRIPTION                  DRUG   COV-
                                  16               ERAGE.—The                     monthly beneficiary premium for
                                  17               qualified prescription drug coverage and access to
                                  18               negotiated prices described in section 1860D–
                                  19               2(a)(1)(A) to be charged under a Medicare operated
                                  20               prescription drug plan shall be uniform nationally.
                                  21               Such premium for months in 2014 and each suc-
                                  22               ceeding year shall be based on the average monthly
                                  23               per capita actuarial cost of offering the Medicare op-




                                  24               erated prescription drug plan for the year involved,
                                  25               including administrative expenses.


                                              •S 408 IS

                                    1                        ‘‘(2) SUPPLEMENTAL          4           PRESCRIPTION DRUG COV-
                                    2              ERAGE.—Insofar                    as a Medicare operated prescrip-
                                    3              tion drug plan offers supplemental prescription drug
                                    4              coverage, the Secretary may adjust the amount of
                                    5              the premium charged under paragraph (1).
                                    6              ‘‘(e) USE OF A FORMULARY AND FORMULARY INCEN-
                                    7     TIVES.—

                                    8                        ‘‘(1) IN       GENERAL.—With                      respect to the oper-
                                    9              ation of a Medicare operated prescription drug plan,
                                  10               the Secretary shall establish and apply a formulary
                                  11               (and may include formulary incentives described in
                                  12               paragraph (2)(C)(ii)) in accordance with this sub-
                                  13               section in order to—
                                  14                                  ‘‘(A) increase patient safety;
                                  15                                  ‘‘(B) increase appropriate use and reduce
                                  16                         inappropriate use of drugs; and
                                  17                                  ‘‘(C) reward value.
                                  18                         ‘‘(2) DEVELOPMENT                     OF INITIAL FORMULARY.—

                                  19                                  ‘‘(A) IN         GENERAL.—In                    selecting covered
                                  20                         part D drugs for inclusion in a formulary, the
                                  21                         Secretary shall consider clinical benefit and
                                  22                         price.
                                  23                                  ‘‘(B) ROLE             OF AHRQ.—The                   Director of the




                                  24                         Agency for Healthcare Research and Quality
                                  25                         shall be responsible for assessing the clinical


                                              •S 408 IS

                                                                                             5
                                    1                        benefit of covered part D drugs and making
                                    2                        recommendations to the Secretary regarding
                                    3                        which drugs should be included in the for-
                                    4                        mulary. In conducting such assessments and
                                    5                        making such recommendations, the Director
                                    6                        shall—
                                    7                                        ‘‘(i) consider safety concerns including
                                    8                                 those identified by the Federal Food and
                                    9                                 Drug Administration;
                                  10                                         ‘‘(ii) use available data and evalua-
                                  11                                  tions, with priority given to randomized
                                  12                                  controlled trials, to examine clinical effec-
                                  13                                  tiveness, comparative effectiveness, safety,
                                  14                                  and enhanced compliance with a drug regi-
                                  15                                  men;
                                  16                                         ‘‘(iii) use the same classes of drugs
                                  17                                  developed by the United States Pharma-
                                  18                                  copeia for this part;
                                  19                                         ‘‘(iv) consider evaluations made by—
                                  20                                                   ‘‘(I) the Director under section
                                  21                                         1013 of the Medicare Prescription
                                  22                                         Drug, Improvement, and Moderniza-
                                  23                                         tion Act of 2003;





                                              •S 408 IS

                                                                                             6
                                    1                                                  ‘‘(II) other Federal entities, such
                                    2                                        as the Secretary of Veterans Affairs;
                                    3                                        and
                                    4                                                  ‘‘(III) other private and public
                                    5                                        entities, such as the Drug Effective-
                                    6                                        ness Review Project and State plans
                                    7                                        under title XIX; and
                                    8                                        ‘‘(v) recommend to the Secretary—
                                    9                                                  ‘‘(I) those drugs in a class that
                                  10                                         provide a greater clinical benefit, in-
                                  11                                         cluding fewer safety concerns or less
                                  12                                         risk of side-effects, than another drug
                                  13                                         in the same class that should be in-
                                  14                                         cluded in the formulary;
                                  15                                                   ‘‘(II) those drugs in a class that
                                  16                                         provide less clinical benefit, including
                                  17                                         greater safety concerns or a greater
                                  18                                         risk of side-effects, than another drug
                                  19                                         in the same class that should be ex-
                                  20                                         cluded from the formulary; and
                                  21                                                   ‘‘(III) drugs in a class with same
                                  22                                         or similar clinical benefit for which it
                                  23                                         would be appropriate for the Sec-




                                  24                                         retary to competitively bid (or nego-
                                  25                                         tiate) for placement on the formulary.


                                              •S 408 IS

                                                                                             7
                                    1                                 ‘‘(C)       CONSIDERATION                      OF        AHRQ     REC-
                                    2                        OMMENDATIONS.—
                                    3                                         ‘‘(i) IN           GENERAL.—The                      Secretary,
                                    4                                 after taking into consideration the rec-
                                    5                                 ommendations under subparagraph (B)(v),
                                    6                                 shall establish a formulary, and formulary
                                    7                                 incentives, to encourage use of covered
                                    8                                 part D drugs that—
                                    9                                                  ‘‘(I) have a lower cost and pro-
                                  10                                          vide a greater clinical benefit than
                                  11                                          other drugs;
                                  12                                                   ‘‘(II) have a lower cost than
                                  13                                          other drugs with the same or similar
                                  14                                          clinical benefit; and
                                  15                                                   ‘‘(III) have the same cost but
                                  16                                          provide greater clinical benefit than
                                  17                                          other drugs.
                                  18                                          ‘‘(ii) FORMULARY                     INCENTIVES.—The
                                  19                                  formulary incentives under clause (i) may
                                  20                                  be in the form of one or more of the fol-
                                  21                                  lowing:
                                  22                                                   ‘‘(I) Tiered copayments.
                                  23                                                   ‘‘(II) Reference pricing.





                                  24                                                   ‘‘(III) Prior authorization.
                                  25                                                   ‘‘(IV) Step therapy.


                                              •S 408 IS

                                                                                             8
                                    1                                                  ‘‘(V) Medication therapy manage-
                                    2                                        ment.
                                    3                                                  ‘‘(VI) Generic drug substitution.
                                    4                                        ‘‘(iii) FLEXIBILITY.—In applying such
                                    5                                 formulary incentives the Secretary may de-
                                    6                                 cide not to impose any cost-sharing for a
                                    7                                 covered part D drug for which—
                                    8                                                  ‘‘(I) the elimination of cost shar-
                                    9                                        ing would be expected to increase
                                  10                                         compliance with a drug regimen; and
                                  11                                                   ‘‘(II) compliance would be ex-
                                  12                                         pected to produce savings under part
                                  13                                         A or B or both.
                                  14                         ‘‘(3) LIMITATIONS                     ON FORMULARY.—In                any
                                  15               formulary established under this subsection, the for-
                                  16               mulary may not be changed during a year, except—
                                  17                                  ‘‘(A) to add a generic version of a covered
                                  18                         part D drug that entered the market;
                                  19                                  ‘‘(B) to remove such a drug for which a
                                  20                         safety problem is found; and
                                  21                                  ‘‘(C) to add a drug that the Secretary
                                  22                         identifies as a drug which treats a condition for
                                  23                         which there has not previously been a treatment




                                  24                         option or for which a clear and significant ben-
                                              •S 408 IS

                                                                                             9
                                    1                        efit has been demonstrated over other covered
                                    2                        part D drugs.
                                    3                        ‘‘(4) ADDING                DRUGS TO THE INITIAL FOR-
                                    4              MULARY.—
                                    5                                 ‘‘(A) USE         OF ADVISORY COMMITTEE.—The
                                    6                        Secretary shall establish and appoint an advi-
                                    7                        sory committee (in this paragraph referred to
                                    8                        as the ‘advisory committee’)—
                                    9                                        ‘‘(i) to review petitions from drug
                                  10                                  manufacturers, health care provider orga-
                                  11                                  nizations, patient groups, and other enti-
                                  12                                  ties for inclusion of a drug in, or other
                                  13                                  changes to, such formulary; and
                                  14                                         ‘‘(ii) to recommend any changes to the
                                  15                                  formulary established under this sub-
                                  16                                  section.
                                  17                                  ‘‘(B) COMPOSITION.—The advisory com-
                                  18                         mittee shall be composed of 9 members and
                                  19                         shall include representatives of physicians,
                                  20                         pharmacists, and consumers and others with ex-
                                  21                         pertise in evaluating prescription drugs. The
                                  22                         Secretary shall select members based on their
                                  23                         knowledge of pharmaceuticals and the Medicare




                                  24                         population. Members shall be deemed to be spe-
                                  25                         cial Government employees for purposes of ap-


                                              •S 408 IS

                                                                                         10
                                    1                        plying the conflict of interest provisions under
                                    2                        section 208 of title 18, United States Code, and
                                    3                        no waiver of such provisions for such a member
                                    4                        shall be permitted.
                                    5                                 ‘‘(C) CONSULTATION.—The advisory com-
                                    6                        mittee shall consult, as necessary, with physi-
                                    7                        cians who are specialists in treating the disease
                                    8                        for which a drug is being considered.
                                    9                                 ‘‘(D) REQUEST                 FOR STUDIES.—The               advi-
                                  10                         sory committee may request the Agency for
                                  11                         Healthcare Research and Quality or an aca-
                                  12                         demic or research institution to study and make
                                  13                         a report on a petition described in subpara-
                                  14                         graph (A)(i) in order to assess—
                                  15                                         ‘‘(i) clinical effectiveness;
                                  16                                         ‘‘(ii) comparative effectiveness;
                                  17                                         ‘‘(iii) safety; and
                                  18                                         ‘‘(iv) enhanced compliance with a
                                  19                                  drug regimen.
                                  20                                  ‘‘(E) RECOMMENDATIONS.—The advisory
                                  21                         committee shall make recommendations to the
                                  22                         Secretary regarding—
                                  23                                         ‘‘(i) whether a covered part D drug is




                                  24                                  found to provide a greater clinical benefit,
                                  25                                  including fewer safety concerns or less risk


                                              •S 408 IS

                                                                                         11
                                    1                                 of side-effects, than another drug in the
                                    2                                 same class that is currently included in the
                                    3                                 formulary and should be included in the
                                    4                                 formulary;
                                    5                                        ‘‘(ii) whether a covered part D drug is
                                    6                                 found to provide less clinical benefit, in-
                                    7                                 cluding greater safety concerns or a great-
                                    8                                 er risk of side-effects, than another drug in
                                    9                                 the same class that is currently included in
                                  10                                  the formulary and should not be included
                                  11                                  in the formulary; and
                                  12                                         ‘‘(iii) whether a covered part D drug
                                  13                                  has the same or similar clinical benefit to
                                  14                                  a drug in the same class that is currently
                                  15                                  included in the formulary and whether the
                                  16                                  drug should be included in the formulary.
                                  17                                  ‘‘(F) LIMITATIONS                    ON REVIEW OF MANU-
                                  18                         FACTURER               PETITIONS.—The                          advisory   com-
                                  19                         mittee shall not review a petition of a drug
                                  20                         manufacturer under subparagraph (A)(i) with
                                  21                         respect to a covered part D drug unless the pe-
                                  22                         tition is accompanied by the following:
                                  23                                         ‘‘(i) Raw data from clinical trials on




                                  24                                  the safety and effectiveness of the drug.
                                              •S 408 IS

                                                                                         12
                                    1                                         ‘‘(ii) Any data from clinical trials con-
                                    2                                 ducted using active controls on the drug or
                                    3                                 drugs that are the current standard of
                                    4                                 care.
                                    5                                         ‘‘(iii) Any available data on compara-
                                    6                                 tive effectiveness of the drug.
                                    7                                         ‘‘(iv) Any other information the Sec-
                                    8                                 retary requires for the advisory committee
                                    9                                 to complete its review.
                                  10                                  ‘‘(G) RESPONSE                TO RECOMMENDATIONS.—
                                  11                         The Secretary shall review the recommenda-
                                  12                         tions of the advisory committee and if the Sec-
                                  13                         retary accepts such recommendations the Sec-
                                  14                         retary shall modify the formulary established
                                  15                         under this subsection accordingly. Nothing in
                                  16                         this section shall preclude the Secretary from
                                  17                         adding to the formulary a drug for which the
                                  18                         Director of the Agency for Healthcare Research
                                  19                         and Quality or the advisory committee has not
                                  20                         made a recommendation.
                                  21                                  ‘‘(H) NOTICE                 OF        CHANGES.—The          Sec-
                                  22                         retary shall provide timely notice to bene-
                                  23                         ficiaries and health professionals about changes




                                  24                         to the formulary or formulary incentives.
                                              •S 408 IS

                                                                                         13
                                    1              ‘‘(f) INFORMING BENEFICIARIES.—The Secretary
                                    2 shall take steps to inform beneficiaries about the avail-
                                    3 ability of a Medicare operated drug plan or plans including
                                    4 providing information in the annual handbook distributed
                                    5 to all beneficiaries and adding information to the official
                                    6 public Medicare website related to prescription drug cov-
                                    7 erage available through this part.
                                    8              ‘‘(g) APPLICATION                   OF      ALL OTHER REQUIREMENTS
                                    9     FOR      PRESCRIPTION DRUG PLANS.—Except as specifically
                                  10 provided in this section, any Medicare operated drug plan
                                  11 shall meet the same requirements as apply to any other
                                  12 prescription drug plan, including the requirements of sec-
                                  13 tion 1860D–4(b)(1) relating to assuring pharmacy ac-
                                  14 cess.’’.
                                  15               (b) CONFORMING AMENDMENTS.—
                                  16                         (1) Section 1860D–3(a) of the Social Security
                                  17               Act (42 U.S.C. 1395w–103(a)) is amended by add-
                                  18               ing at the end the following new paragraph:
                                  19                         ‘‘(4) AVAILABILITY                    OF THE MEDICARE OPER-
                                  20               ATED PRESCRIPTION DRUG PLAN.—A                                             Medicare op-
                                  21               erated prescription drug plan (as defined in section
                                  22               1860D–11A(c)) shall be offered nationally in accord-
                                  23               ance with section 1860D–11A.’’.





                                              •S 408 IS

                                                                                         14
                                    1                        (2)(A) Section 1860D–3 of the Social Security
                                    2              Act (42 U.S.C. 1395w–103) is amended by adding
                                    3              at the end the following new subsection:
                                    4              ‘‘(c) PROVISIONS ONLY APPLICABLE                                                IN   2006
                                    5 THROUGH 2013.—The provisions of this section shall only
                                    6 apply with respect to 2006 through 2013.’’.
                                    7                        (B) Section 1860D–11(g) of such Act (42
                                    8              U.S.C. 1395w–111(g)) is amended by adding at the
                                    9              end the following new paragraph:
                                  10                         ‘‘(8) NO             AUTHORITY FOR FALLBACK PLANS
                                  11               AFTER 2013.—A                  fallback prescription drug plan shall
                                  12               not be available after December 31, 2013.’’.
                                  13                         (3) Section 1860D–13(c)(3) of the Social Secu-
                                  14               rity Act (42 U.S.C. 1395w–113(c)(3)) is amended—
                                  15                                  (A) in the heading, by inserting ‘‘AND
                                  16                         MEDICARE               OPERATED                PRESCRIPTION                DRUG
                                  17                         PLANS’’       after ‘‘FALLBACK                   PLANS’’;         and
                                  18                                  (B) by inserting ‘‘or a Medicare operated
                                  19                         prescription drug plan’’ after ‘‘a fallback pre-
                                  20                         scription drug plan’’.
                                  21                         (4) Section 1860D–16(b)(1) of the Social Secu-
                                  22               rity Act (42 U.S.C. 1395w–116(b)(1)) is amended—
                                  23                                  (A) in subparagraph (C), by striking





                                  24                         ‘‘and’’ after the semicolon at the end;




                                              •S 408 IS

                                                                                         15
                                    1                                 (B) in subparagraph (D), by striking the
                                    2                        period at the end and inserting ‘‘; and’’; and
                                    3                                 (C) by adding at the end the following new
                                    4                        subparagraph:
                                    5                                 ‘‘(E) payments for expenses incurred with
                                    6                        respect to the operation of Medicare operated
                                    7                        prescription drug plans under section 1860D–
                                    8                        11A.’’.
                                    9                        (5) Section 1860D–41(a) of the Social Security
                                  10               Act (42 U.S.C. 1395w–151(a)) is amended by add-
                                  11               ing at the end the following new paragraph:
                                  12                         ‘‘(19) MEDICARE                       OPERATED                  PRESCRIPTION
                                  13               DRUG PLAN.—The                     term ‘Medicare operated prescrip-
                                  14               tion drug plan’ has the meaning given such term in
                                  15               section 1860D–11A(c).’’.
                                  16      SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDI-
                                  17                              CARE OPERATED PRESCRIPTION DRUG PLAN.
                                  18               Section 1860D–4(h) of the Social Security Act (42
                                  19 U.S.C. 1305w–104(h)) is amended by adding at the end
                                  20 the following new paragraph:
                                  21                         ‘‘(4) APPEALS               PROCESS FOR MEDICARE OPER-
                                  22               ATED PRESCRIPTION DRUG PLAN.—
                                  23                                  ‘‘(A) IN         GENERAL.—The                         Secretary shall




                                  24                         develop a well-defined process for appeals for
                                  25                         denials of benefits under this part under the


                                              •S 408 IS

                                                                                         16
                                    1                        Medicare operated prescription drug plan. Such
                                    2                        process shall be efficient, impose minimal ad-
                                    3                        ministrative burdens, and ensure the timely
                                    4                        procurement of non-formulary drugs or exemp-
                                    5                        tion from formulary incentives when medically
                                    6                        necessary. Medical necessity shall be based on
                                    7                        professional medical judgment, the medical con-
                                    8                        dition of the beneficiary, and other medical evi-
                                    9                        dence. Such appeals process shall include—
                                  10                                         ‘‘(i) an initial review and determina-
                                  11                                  tion made by the Secretary; and
                                  12                                         ‘‘(ii) for appeals denied during the ini-
                                  13                                  tial review and determination, the option of
                                  14                                  an external review and determination by
                                  15                                  an independent entity selected by the Sec-
                                  16                                  retary.
                                  17                                  ‘‘(B) CONSULTATION                      IN DEVELOPMENT OF
                                  18                         PROCESS.—In                developing the appeals process
                                  19                         under subparagraph (A), the Secretary shall
                                  20                         consult with consumer and patient groups, as
                                  21                         well as other key stakeholders to ensure the
                                  22                         goals        described              in      subparagraph              (A)   are
                                  23                         achieved.’’.
                                              •S 408 IS                                    Æ
